GlobeNewswire

Nine EPAM Experts Named Sitecore® Most Valuable Professionals

Dela

Elite Distinction Awarded for Exceptional Contributions to the Sitecore Ecosystem

NEWTOWN, Pa., Feb. 01, 2018 (GLOBE NEWSWIRE) -- EPAM Systems, Inc. (NYSE:EPAM), a leading global provider of digital platform engineering and software development solutions, today announced that nine of its experts have been named "Most Valuable Professionals (MVPs)" by Sitecore®, the global leader in experience management software, including:

  • David Mead, one of only 63 Ambassador MVPs
  • Jon Riekse, one of only 39 Strategy MVPs
  • Saurabh Sachdeva and Dean Thrasher, two of only 19 Commerce MVPs
  • Pavel Veller, Aliaksandr Smahin, Zachary Kniebel, Brent Pinkstaff and Dmytro Shevchenko, five of 208 Technology MVPs worldwide

Now in its 12th year, Sitecore's MVP program recognizes individual technology, strategy, and commerce advocates who share their Sitecore passion and expertise to offer positive customer experiences that drive business results. The Sitecore MVP Award recognizes the most active Sitecore experts from around the world who participate in online and offline communities to share their knowledge with other Sitecore partners and customers.

"We are so proud that nine of our Sitecore experts - the most ever for our company - have been recognized with this distinction," said Valeri Makovik, VP, Technology Solutions, EPAM. "This recognition not only shows the depth and global reach of our Sitecore experience, with at least one EPAM expert represented in every MVP category, but also reflects our deep commitment to the broader Sitecore community and to our customers who choose Sitecore as their platform of choice."

Over the last 11 years, EPAM's 300+ Sitecore professionals have delivered more than 100 projects for 50+ global customers. As one of Sitecore's elite Platinum Partners in the US, a Gold Solution Partner in the UK and an Implementation Partner in APAC, EPAM delivers large-scale, omnichannel digital marketing solutions that ensure a seamless digital experience for its global customers. EPAM has utilized its Sitecore expertise to build four accelerators for businesses to quickly take advantage of Sitecore's platform without having to create their own digital solution, including EPAM's Sitecore Retail AcceleratorSitecore SAP Hybris ConnectorEngX Accelerator and Sitecore Aprimo DAM Connector.

"The Sitecore MVP awards recognize and honor those individuals who make substantial contributions to our loyal community of partners and customers," said Pieter Brinkman, Sitecore Senior Director of Technical Marketing. "MVPs consistently set a standard of excellence by delivering technical chops, enthusiasm, and a commitment to giving back to the Sitecore community. They truly understand and deliver on the power of the Sitecore Experience Platform to create personalized brand experiences for their consumers, driving revenue and customer loyalty."

The Sitecore Experience Platform(TM) combines web content management, omnichannel digital delivery, insights into customer activity and engagement, and strategic digital marketing tools into a single, unified platform. Sitecore Experience Commerce(TM) 9, released in January 2018, is the only cloud-enabled platform that natively integrates content and commerce so brands can fully personalize and individualize the end-to-end shopping experience before, during, and after the transaction. Both platforms capture in real time every minute interaction-and intention-that customers and prospects have with a brand across digital and offline channels. The result is that Sitecore customers are able to use the platform to engage with prospects and customers in a highly personalized manner, earning long-term customer loyalty.

For more information about EPAM's Sitecore expertise, visit www.epam.com/sitecore. Information about Sitecore's MVP program can be found here: http://www.sitecore.com/mvp.

About EPAM Systems
Since 1993, EPAM Systems, Inc. (NYSE:EPAM) has leveraged its core engineering expertise to become a leading global product development and digital platform engineering services company. Through its 'Engineering DNA' and innovative strategy, consulting, and design capabilities, EPAM works in collaboration with its customers to deliver innovative solutions that turn complex business challenges into real business opportunities. EPAM's global teams serve customers in over 25 countries across North America, Europe, Asia and Australia. EPAM is a recognized market leader among independent research agencies and was ranked #12 in FORBES 25 Fastest Growing Public Tech Companies, as a top information technology services company on FORTUNE'S 100 Fastest-Growing Companies, and as a top UK Digital Design & Build Agency. Learn more at http://www.epam.com/ and follow us on Twitter @EPAMSYSTEMS and LinkedIn.

Forward-Looking Statements 
This press release includes statements which may constitute forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the accuracy of which are necessarily subject to risks, uncertainties, and assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ materially from those expressed or implied include general economic conditions and the factors discussed in our most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. EPAM undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required under applicable securities law.

CONTACT: Danielle Ruess-Saltz
M: 267.978.7688
danielle_ruess-saltz@epam.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: EPAM Systems, Inc via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Aprea Therapeutics appoints a new Chief Medical Officer25.3.2019 11:00:00 CETPressmeddelande

STOCKHOLM, March 25, 2019. Karolinska Development's portfolio company Aprea Therapeutics announces today that Dr. Eyal C. Attar has been appointed to a position as Senior Vice President and Chief Medical Officer (CMO). Dr. Attar joins Aprea from Agios Pharmaceuticals, where he was Senior Medical Director and IDH Hematology Medical Lead. Having served at Agios since 2014, Dr. Attar played a leadership role in the clinical development and approval of Idhifa and Tibsovo for patients with relapsed/refractory Acute Myeloid Leukemia (AML). Prior to Agios, he served on the clinical staff at the Massachusetts General Hospital Cancer Center, where Dr. Attar was a member of the Center for Leukemia and Assistant Professor of Medicine at Harvard Medical School. "Dr. Attar's deep medical and biotech industry experiences will strengthen our clinical development efforts as we continue to advance our first-in-class p53 reactivating agents in late-stage clinical studies", states Christian S. Schade, Pr

Karolinska Development's portfolio company Aprea Therapeutics appoints a new Chief Medical Officer25.3.2019 11:00:00 CETPressmeddelande

STOCKHOLM, March 25, 2019. Karolinska Development's portfolio company Aprea Therapeutics announces today that Dr. Eyal C. Attar has been appointed to a position as Senior Vice President and Chief Medical Officer (CMO). Dr. Attar joins Aprea from Agios Pharmaceuticals, where he was Senior Medical Director and IDH Hematology Medical Lead. Having served at Agios since 2014, Dr. Attar played a leadership role in the clinical development and approval of Idhifa and Tibsovo for patients with relapsed/refractory Acute Myeloid Leukemia (AML). Prior to Agios, he served on the clinical staff at the Massachusetts General Hospital Cancer Center, where Dr. Attar was a member of the Center for Leukemia and Assistant Professor of Medicine at Harvard Medical School. "Dr. Attar's deep medical and biotech industry experiences will strengthen our clinical development efforts as we continue to advance our first-in-class p53 reactivating agents in late-stage clinical studies", states Christian S. Schade, Pr

Immunicum AB (publ) meddelar kommande konferenser i mars och april22.3.2019 08:00:00 CETPressmeddelande

Pressmeddelande 22 mars 2019 Immunicum AB (publ) meddelar kommande konferenser i mars och april Immunicum AB (publ; IMMU.ST) meddelar idag att medlemmar av ledningsgruppen kommer att delta och presentera vid kommande konferenser i mars och april. BIO-Europe Spring Datum: 25-27 mars 2019 Plats: Messe Wien Exhibition and Congress Center, Wien, Österrike Deltagare: Sijme Zeilemaker China Focus @ Europe Vienna Datum: 27 mars 2019 Paneltid/Sessionstid: 16.10 - 17.00, Panel 4: Partnering Opportunities with Chinese Pharma Plats: Hilton Vienna Danube Waterfront, Wien, Österrike Deltagare: Carlos de Sousa Swedish American Life Science Summit 2019 Datum: 9-10 april 2019 Presentationsdatum: Onsdagen 10 april 2019 Plats: House of Sweden, 2900 K St. NW, Washington D.C. 20008 Deltagare: Carlos de Sousa För ytterligare information kontakta: Carlos de Sousa, VD, Immunicum Telefon: +46 8 732 8400 E-post: info@immunicum.com Michaela Gertz, Finanschef, Immunicum Telefon: +46 (0) 70 926 17 75 E-post: ir@i

Immunicum AB (publ) Announces Upcoming Conferences in March and April22.3.2019 08:00:00 CETPressmeddelande

Press Release 22 March 2019 Immunicum AB (publ) Announces Upcoming Conferences in March and April Immunicum AB (publ; IMMU.ST) announced today that members of the management team will attend and present at upcoming conferences in March and April. BIO-Europe Spring Date: March 25-27, 2019 Venue: Messe Wien Exhibition and Congress Center, Vienna, Austria Participant: Sijme Zeilemaker China Focus @ Europe Vienna Date: March 27, 2019 Panel Time/Session: 16.10 - 17.00, Panel 4: Partnering Opportunities with Chinese Pharma Venue: Hilton Vienna Danube Waterfront, Vienna, Austria Participant: Carlos de Sousa Swedish American Life Science Summit 2019 Date: April 9-10, 2019 Presentation Date: Wednesday, April 10, 2019 Venue: House of Sweden, 2900 K St. NW, Washington D.C. 20008 Participant: Carlos de Sousa For more information, please contact: Carlos de Sousa, CEO, Immunicum Telephone: +46 8 732 8400 E-mail: info@immunicum.com Michaela Gertz, CFO, Immunicum Telephone: +46 70 926 17 75 E-mail: ir

Karolinska Development's portfolio company Promimic announces partnership with Onkos Surgical15.3.2019 08:45:00 CETPressmeddelande

STOCKHOLM, March 15, 2019. Karolinska Development's portfolio company Promimic announces a new partnership with the U.S company Onkos Surgical® to commercialize Promimic's proprietary Hydroxyapatite (HA) Surface Technologies in Limb Salvage Surgery. Promimic develops and markets products within nano-materials for innovative surface treatments and has developed the HA nano Surface that is clinically proven to speed up and improve the anchoring of implants in bone. The innovative technology is already licensed to several dental implant companies. The partnership with Onkos Surgical®, a U.S company addressing the clinical challenges associated with tumor surgery, represents an important step into the orthopaedic space. The partnership will focus on combining Promimic's HA nano Surface Technology with Onkos Surgical®'s ELEOS Limb Salvage Portfolio. Implant failure due to aseptic loosening remains one of the key challenges associated with limb salvage surgery. With HA nano Surface, Onkos Su

Karolinska Development's portfolio company Promimic announces partnership with Onkos Surgical15.3.2019 08:45:00 CETPressmeddelande

STOCKHOLM, March 15, 2019. Karolinska Development's portfolio company Promimic announces a new partnership with the U.S company Onkos Surgical® to commercialize Promimic's proprietary Hydroxyapatite (HA) Surface Technologies in Limb Salvage Surgery. Promimic develops and markets products within nano-materials for innovative surface treatments and has developed the HA nano Surface that is clinically proven to speed up and improve the anchoring of implants in bone. The innovative technology is already licensed to several dental implant companies. The partnership with Onkos Surgical®, a U.S company addressing the clinical challenges associated with tumor surgery, represents an important step into the orthopaedic space. The partnership will focus on combining Promimic's HA nano Surface Technology with Onkos Surgical®'s ELEOS Limb Salvage Portfolio. Implant failure due to aseptic loosening remains one of the key challenges associated with limb salvage surgery. With HA nano Surface, Onkos Su

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum